Linked Life Data

16832162

Source:http://linkedlifedata.com/resource/pubmed/id/16832162

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-7-11
pubmed:abstractText
Cholesteryl ester transfer protein (CETP) inhibitors (JTT-705 and torcetrapib) are currently in clinical testing, and significantly raise high-density lipoprotein (HDL) cholesterol levels. Low HDL cholesterol is a significant independent predictor of coronary heart disease (CHD) and HDL raising has been associated with coronary heart disease risk reduction, but there is debate about whether CETP inhibition will reduce coronary heart disease risk.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0957-9672
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
394-8
pubmed:dateRevised
2009-10-8
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
pubmed:affiliation
Cardiovascular Research and Lipid Metabolism Laboratories, Tufts University, Boston, Massachusetts, USA. ernst.schaefer@tufts.edu
pubmed:publicationType
Journal Article, Review